Elizabeth Arden
This article was originally published in The Rose Sheet
Executive Summary
Firm announces proposed underwritten public offering of 4,000,000 shares of its common stock, according to preliminary prospectus supplement to existing shelf registration statement filed Oct. 2 with the Securities & Exchange Commission. Offering will comprise 2,666,667 shares offered by Elizabeth Arden, in addition to 1,333,333 shares offered by Unilever, although company will not receive any of net proceeds from sale of Unilever shares. Arden says it will use net proceeds to redeem part of its 11 3/4% Senior Secured Notes due 2011...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.